TELA Bio, Inc. reported Q4 loss, missed revenue estimates by 24.25%.

From Nasdaq: 2025-03-20 18:50:06

TELA Bio, Inc. reported a quarterly loss of $0.23 per share, in line with estimates and an improvement from a loss of $0.53 per share last year. Revenues of $17.65 million missed estimates by 24.25%. The stock has declined 21.9% this year. Investors are now looking at the company’s earnings outlook to determine future performance.

While TELA Bio underperformed the market, its earnings outlook is crucial for investors. The company’s estimate revisions trend is mixed, leading to a Zacks Rank #3 (Hold). The current consensus EPS estimate is -$0.30 for the next quarter and -$0.66 for the fiscal year. Industry outlook also impacts stock performance.

In the same industry, BioXcel Therapeutics, Inc. is yet to report results for the quarter. It is expected to post a quarterly loss of $4.36 per share, with revenues expected to be $0.15 million, down 60.5% from the year-ago quarter. The consensus EPS estimate has remained unchanged.

For investors considering TELA Bio, Inc., Zacks Investment Research offers insights and analysis on the best stocks to buy. The Zacks Rank system has a strong track record, outperforming the S&P 500 with an average gain of +24.08% per year. Download the report for the 7 best stocks for the next 30 days.



Read more at Nasdaq: TELA Bio, Inc. (TELA) Reports Q4 Loss, Misses Revenue Estimates